Results 51 to 60 of about 36,162 (179)

Impact of evolving treatment patterns on interstitial lung disease progression in systemic sclerosis using the EUSTAR database

Arthritis &Rheumatology, Accepted Article.
Background The treatment landscape for systemic sclerosis‐associated interstitial lung disease (SSc‐ILD) has evolved with increasing immunosuppressive (IST) and anti‐fibrotic therapies available. However, their real‐world use remains unclear. Objectives To analyze treatment trends and the effect of IST and anti‐fibrotic therapies on ILD progression ...
Corrado Campochiaro, Marie‐Elise Truchetet, Madelon Vonk, Giacomo De Luca, Giovanna Cuomo, Lidia P. Ananieva, Eric Hachulla, Vanessa Smith, Ana Maria Gheorghiu, Radim Becvar, Patricia Carreira, Nicolas Hunzelmann, Daniel E. Furst, Vera Ortiz‐Santamaria, Francesco Del Galdo, Marco Matucci‐Cerinic, Anna‐Maria Hoffmann‐Vold, EUSTAR collaborators   +17 more
wiley   +1 more source

A rare cutaneous manifestation of systemic sclerosis

European Journal of Case Reports in Internal Medicine
A 43-year-old male with a history of intravenous drug use and alcohol consumption presented to the emergency department with three-month history of failure to thrive.
Joelle Sleiman, Taimur Aslam, Anastasia Slobodnick, Alina G. Bridges   +3 more
doaj   +1 more source

Interstitial Lung Disease in ANCA‐Associated Vasculitis: A European Multicentre Study

Arthritis &Rheumatology, Accepted Article.
Background Interstitial Lung Disease (ILD) can occur in association with ANCA‐associated Vasculitis (AAV‐ILD) or as an isolated entity with positive ANCA (ANCA‐ILD). However, data on the epidemiology and outcomes of these conditions remain limited.
Aglaia Chalkia, Marusa Kotnik, Timothy J Sadler, Spyridon Katechis, Rachel Jones, Ajay Kamath, Aladdin J Mohammad, Sara Monti, Chetan Mukhtyar, Viral Nanda, Ioannis Petrakis, Dimitrios Petras, Ashnish Sinha, Pasupathy Sivasothy, Rona Smith, Kostas Stylianou, Dimitrios Vassilopoulos, Judith Babar, David Jayne   +18 more
wiley   +1 more source

Long Non‐Coding RNA H19 mediates STAT3 dependent activation of keratinocytes and fibroblasts in Systemic Sclerosis skin

Arthritis &Rheumatology, Accepted Article.
Objective Dermal Systemic Sclerosis (SSc) fibroblasts and their exosomes can activate keratinocytes in SSc, with lncRNA H19 (H19) highlighted as the most upregulated RNA in their cargo compared to healthy control (HC). The role of H19 in SSc pathogenesis has never been investigated.
Begoña Caballero‐Ruiz, Christopher W Wasson, Rebecca L Ross, Francesco Del Galdo   +3 more
wiley   +1 more source

Assessment of Treatment Response in Patients With Scleromyxedema by the Double Modified Rodnan Skin Score

JEADV Clinical Practice, EarlyView.
ABSTRACT Background Scleromyxedema (SMX) is a cutaneous mucinosis characterised by an abnormal accumulation of mucin in the skin and limited treatment options. Assessment of therapy response during treatment is challenging. Objectives Patients with SMX receiving high‐dose intravenous IVIg therapy were included to assess validity of the double modified ...
Julia K. Winkler, Alexander H. Enk
wiley   +1 more source

Emphysema formation in a never-smoker with scleroderma-related interstitial pneumonia

Respiratory Medicine Case Reports, 2018
We report a case of pathological emphysema formation in a never-smoker with scleroderma-related interstitial pneumonia. We realized the importance of pulmonary vasculopathy causing the coexistence of emphysema and fibrosis in scleroderma.
Hideaki Yamakawa, Tamiko Takemura, Tomohisa Baba, Takashi Ogura   +3 more
doaj   +1 more source

Immunotherapy‐Related Cutaneous Toxicities in Melanoma: A Dermoscopic Perspective

JEADV Clinical Practice, EarlyView.
Dermoscopy serves as a valuable tool in the everyday dermatological and oncological practice for melanoma patients, allowing for the prompt identification of immune‐related cutaneous toxicities and guiding clinicians toward appropriate therapeutic decisions.
Grażyna Kamińska‐Winciorek, Iris Zalaudek, Karolina Zarańska, Bożena Cybulska‐Stopa   +3 more
wiley   +1 more source

National Mortality Databases to Assess Disease Burden in Systemic Autoimmune Diseases: A Valuable Resource But With Limitations

Arthritis &Rheumatology, EarlyView.
Ram Raj Singh
wiley   +1 more source

Cardiac disease in systemic sclerosis: Integrating pathobiology with clinical management

Rheumatology &Autoimmunity, EarlyView.
Abstract Systemic sclerosis (SSc) is a complex autoimmune disorder in which cardiovascular involvement remains a major determinant of morbidity and mortality. Cardiac injury in SSc results from the interplay of microvascular dysfunction, immune‐mediated inflammation, and progressive interstitial and replacement fibrosis, leading to myocardial disease ...
Henry Sutanto, Betty Rachma, Yuliasih
wiley   +1 more source

Bispecific Dual‐Immune Checkpoint Inhibitor Associated Cutaneous Toxicity: A Report of Lorigerlimab Adverse Skin Reaction in Two Cancer Patients

Journal of Cutaneous Pathology, EarlyView.
ABSTRACT Lorigerlimab is a dual bispecific antibody (BsAb) targeting cytotoxic T‐lymphocyte‐associated protein 4 and programmed cell death protein 1 that is used for treatment of advanced solid cancers such as metastatic castration‐resistant prostate carcinoma.
Niloofar Sina, Fiorinda Muhaj, Volha Lenskaya, Doina Ivan, Victor G. Prieto, Jonathan L. Curry   +5 more
wiley   +1 more source